0000000000576543

AUTHOR

R. Dutta

showing 2 related works from this author

SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study

2021

Abstract Background Preoperative SARS-CoV-2 vaccination could support safer elective surgery. Vaccine numbers are limited so this study aimed to inform their prioritization by modelling. Methods The primary outcome was the number needed to vaccinate (NNV) to prevent one COVID-19-related death in 1 year. NNVs were based on postoperative SARS-CoV-2 rates and mortality in an international cohort study (surgical patients), and community SARS-CoV-2 incidence and case fatality data (general population). NNV estimates were stratified by age (18–49, 50–69, 70 or more years) and type of surgery. Best- and worst-case scenarios were used to describe uncertainty. Results NNVs were more favourable in su…

MaleCOVID-19 Vaccinesafe surgery; vaccination modelling; COVID-19Vascular damage Radboud Institute for Health Sciences [Radboudumc 16]MULTICENTERComorbidity030230 surgery0302 clinical medicinephase 3 clinical trial (topic)Case fatality rateProspective StudiesSARS-CoV-2 Vaccination Safe surgeryCOVID-19/epidemiologySARS-CoV-2 ; vaccination ; safe surgeryeducation.field_of_studycase fatality rateVaccinationVaccinationAdolescent; Adult; Aged; COVID-19; COVID-19 Vaccines; Comorbidity; Elective Surgical Procedures; Female; Humans; Male; Middle Aged; Postoperative Complications; Preoperative Period; Prospective Studies; SARS-CoV-2; Vaccination; Young Adulthealth care policyElective Surgical Procedures030220 oncology & carcinogenesisvaccination modellingPreoperative PeriodCOVID-19; SARS-CoV-2; cancer; vaccination; outcome; mortality; infection; modellingCohort studyprospective studyHumanmedicine.medical_specialtyArticle03 medical and health sciencesSARS-CoV-2 vaccinationSDG 3 - Good Health and Well-beingCOVID-19 Vaccines/pharmacologyHumansVaccination/methodsElective surgeryeducationAgedScience & TechnologyElective Surgical Procedureadult; aged; Article; cancer grading; cancer surgery; case fatality rate; computer assisted tomography; elective surgery; female; follow up; health care policy; human; incidence; infection rate; infection risk; major clinical study; male; middle aged; mortality; outcome assessment; phase 3 clinical trial (topic); preoperative care; prospective study; sensitivity analysis; seroprevalence; Severe acute respiratory syndrome coronavirus 2; vaccination; young adult; COVID-19; COVID-19 Vaccines; Comorbidity; Elective Surgical Procedures; Postoperative Complications; Preoperative Period; SARS-CoV-2; Vaccination; surgery.Cura preoperatòriamajor clinical studymortalityinfectionProspective StudieincidenceSurgeryHuman medicinePostoperative Complication610 Medizin und GesundheitAcademicSubjects/MED00910Settore MED/18 - CHIRURGIA GENERALESettore MED/29 - CHIRURGIA MAXILLOFACCIALEcomputer assisted tomographyESTUDOS PROSPECTIVOSsurgerysafe surgeryPostoperative Complicationssensitivity analysisSevere acute respiratory syndrome coronavirus 2preoperative careVacunacióProspective cohort studyseroprevalenceIncidence (epidemiology)covidElective Surgical Procedures/methodsMiddle Agedcancer gradingCOVID vaccinationoutcome/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingSARS-CoV-2; vaccination; surgeryOriginal ArticleFemalecancer surgeryAcademicSubjects/MED00010Life Sciences & BiomedicineAdultCOVID-19 VaccinesAdolescentinternational prospective cohort studyPostoperative Complications/prevention & controlPopulationinfection rateSARS-CoV-2/immunologyNOmodellingYoung Adultmedicinefollow upcancerddc:610infection riskoutcome assessmentLS7_4business.industrySARS-CoV-2Number needed to vaccinatePreoperative careCOVID-193126 Surgery anesthesiology intensive care radiologySettore MED/18Reconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]elective surgeryEmergency medicinebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyThe British Journal of Surgery
researchProduct

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial …

2015

BACKGROUND: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated.METHODS: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population …

Malemedicine.medical_specialtyAcute coronary syndromePopulationLIXisenatide610 Medicine & healthHypoglycemiaPlacebop38 Mitogen-Activated Protein Kinases11171 Cardiocentro Ticino2705 Cardiology and Cardiovascular Medicinelaw.inventionSettore MED/13 - EndocrinologiaAcute Coronary Syndrome; Aged; Cardiovascular Diseases; Double-Blind Method; Female; Glucagon-Like Peptide 1; Humans; Male; Middle Aged; Peptides; Placebos; Protein Kinase Inhibitors; Research Design; p38 Mitogen-Activated Protein Kinases; Cardiology and Cardiovascular MedicinePlacebosLixisenatidechemistry.chemical_compoundRandomized controlled trialDouble-Blind MethodlawGlucagon-Like Peptide 1Internal medicineJournal ArticlemedicineHumansComparative StudyMyocardial infarctionAcute Coronary SyndromeeducationProtein Kinase InhibitorsAgededucation.field_of_studybusiness.industryUnstable anginaResearch Support Non-U.S. Gov'tta3121Middle Agedmedicine.diseaseSurgeryMulticenter StudychemistryCardiovascular DiseasesResearch DesignRandomized Controlled TrialCardiologyFemaleCardiology and Cardiovascular MedicinebusinessPeptides
researchProduct